Quantum BioPharma Ltd. (NASDAQ: QNTM) announced that its licensee, Unbuzzd Wellness Inc., has appointed Michael “Zappy” Zapolin as chief executive officer. Zapolin’s mandate includes financing and listing Unbuzzd on a stock exchange, followed by a nationwide commercial marketing and product rollout in the United States. The transition from former CEO Richard Buzbuzian is already underway, with the company scheduled to go effective as a publicly listed entity in the next quarter. The appointment signals a strategic push to scale Unbuzzd’s consumer-facing business while Quantum BioPharma retains a significant equity and royalty stake.
Unbuzzd markets unbuzzd™, a beverage designed to accelerate alcohol metabolism, restore mental clarity, and reduce hangover symptoms. The company said the product is backed by a peer-reviewed clinical study and is currently available through Amazon and its website. The move to bring in a high-profile CEO with experience in building and financing consumer brands could accelerate Unbuzzd’s path to broader distribution and brand recognition. For Quantum BioPharma, the licensee’s success could translate into substantial royalty streams and enhanced value for its retained ownership stake.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd and is entitled to royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum also retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The appointment of Zapolin as CEO is a critical step in Unbuzzd’s evolution from a product launch to a publicly traded company. A successful listing would provide Unbuzzd with access to capital markets, enabling it to fund marketing, expand distribution, and potentially accelerate revenue growth. For Quantum BioPharma shareholders, the upside is twofold: a rising equity value in Unbuzzd and a growing royalty stream that could reach $250 million before stepping down. The nationwide rollout in the U.S. also positions unbuzzd™ to capture a larger share of the functional beverage market, particularly among consumers seeking science-backed solutions for alcohol consumption.
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
